Artbio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 74

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $132M

  • Investors
  • 11

Artbio General Information

Description

Operator of a radiopharmaceutical company intended to offer a new approach to the treatment of cancer. The company specializes in radioligand therapy, which delivers alpha or beta emitters to break down cancer cell DNA and build an ecosystem that maximizes the potential of the therapy, enabling medical practitioners to utilize novel mechanisms in oncology.

Contact Information

Website
www.artbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Kendall Square, B200
  • Suite 001
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • One Kendall Square, B200
  • Suite 001
  • Cambridge, MA 02139
  • United States

Artbio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Artbio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 29-Jul-2025 $132M Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 07-Dec-2023 Completed Pre-Clinical Trials
1. Seed Round 21-Jun-2023 $23M $23M Completed Pre-Clinical Trials
To view Artbio’s complete valuation and funding history, request access »

Artbio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed-1
Seed 11,148,808 $0.000010 $2.1 $2.1 1x $2.1 21.07%
To view Artbio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Artbio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a radiopharmaceutical company intended to offer a new approach to the treatment of cancer. The company speci
Drug Discovery
Cambridge, MA
74 As of 2026

South San Francisco, CA
 

Menlo Park, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Artbio Competitors (42)

One of Artbio’s 42 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Radionetics Oncology Venture Capital-Backed Menlo Park, CA
ExCellThera Accelerator/Incubator Backed Montreal, Canada
RadioMedix Venture Capital-Backed Houston, TX
Navidea Biopharmaceuticals Corporate Backed or Acquired Columbus, OH
You’re viewing 5 of 42 competitors. Get the full list »

Artbio Patents

Artbio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226835-A1 Integrin targeting radiotherapeutic compositions and uses thereof Pending 23-Apr-2025
WO-2026207185-A1 Gaseous emanation radionuclide generators and methods including environmental control Pending 26-Mar-2025
AU-2025268764-A1 Radionuclide source holders and methods of operation Pending 07-May-2024
WO-2025235562-A1 Radionuclide source holders and methods of operation Pending 07-May-2024
AU-2025247169-A1 Radionuclide source clip attachment system Pending 29-Mar-2024 A61N5/1007
To view Artbio’s complete patent history, request access »

Artbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Artbio Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
B Capital Group Venture Capital Minority
Bow River Capital PE/Buyout Minority
Qatar Investment Authority Sovereign Wealth Fund Minority
Baker Brothers Investments Hedge Fund Minority
You’re viewing 5 of 11 investors. Get the full list »

Artbio FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process